The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Challenges and future directions for antibody-drug conjugates (ADCs) in lung cancer therapy
Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, comments on the challenges and future directions of antibody drug conjugates (ADCs) in cancer therapy, highlighting the need to understand the complex interactions between the ADC’s structure, internalization, processing, and resistance mechanisms to chemotherapy. Dr Newsom-Davis notes that while some ADCs have shown modest activity, the lack of clear biomarkers and limited immunohistochemistry tools hinder their widespread adoption, and emphasizes the importance of developing bespoke biomarkers to accurately target patients. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
